UK markets close in 43 minutes

Oncopeptides AB (publ) (0RN4.IL)

IOB - IOB Delayed price. Currency in SEK
Add to watchlist
3.0500-0.3025 (-9.02%)
As of 12:47PM BST. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
35,220
35,220
8,355
118,295
0
Cost of revenue
-1,079
-1,079
6
53,121
-
Gross profit
36,299
36,299
8,349
65,174
0
Operating expenses
Research development
106,948
106,948
217,657
679,926
866,214
Selling general and administrative
188,479
188,479
142,195
873,805
654,191
Total operating expenses
290,843
290,843
360,485
1,486,091
1,591,279
Operating income or loss
-254,544
-254,544
-352,136
-1,420,917
-1,591,279
Interest expense
528
5,785
883
948
1,485
Income before tax
-248,447
-248,447
-337,680
-1,421,372
-1,592,442
Income tax expense
664
664
271
8,946
2,251
Income from continuing operations
-249,111
-249,111
-337,951
-1,430,318
-1,594,693
Net income
-249,111
-249,111
-337,951
-1,430,317
-1,594,693
Net income available to common shareholders
-249,111
-249,111
-337,951
-1,430,317
-1,594,693
Basic EPS
-2.87
-
-2.93
-13.54
-18.22
Diluted EPS
-2.87
-
-2.93
-13.54
-18.22
Basic average shares
90,299
-
115,513
105,651
87,517
Diluted average shares
90,299
-
115,513
105,651
87,517